drugset / Trial / NCT00757237

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

NCT00757237

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to assess the comparative safety and effectiveness of aztreonam for inhalation solution versus tobramycin inhalation solution in adult and pediatric patients with cystic fibrosis (CF) and pulmonary Pseudomonas aeruginosa (PA) infection.

Timeline

Start
2008-08
Primary completion
2010-05
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Aztreonam Small molecule 75 mg Inhaled
Comparator Tobramycin Small molecule 300 mg Inhaled

Indications